FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2949681720> ?p ?o ?g. }

• W2949681720 endingPage "762" @default.
• W2949681720 startingPage "761" @default.
• W2949681720 abstract "Background: Acquired thrombotic thrombocytopenic purpura (aTTP) is an immune-mediated life-threatening thrombotic microangiopathy (TMA). Daily therapeutic plasma exchange (TPE) and the optimized use of rituximab have dramatically improved the overall prognosis, however the rate of disease recurrence remains high. Acute-phase treatment and specific predictors of relapse can be relevant for an optimal patient management. Aims: In a large multicenter cohort of aTTP patients, we aimed to analyze the effect of acute-phase treatment on disease recurrence and to identify predictive variables of relapse. Methods: From 2002 to 2018, 325 TMA were referred to our Centers. A complete ADAMTS13 activity deficiency (<10%) was diagnostic for TTP in 163 patients. An anti-ADAMTS13 Ab titer >15U/L was considered positive and identified aTTP cases. Seventy-four aTTP patients with complete medical records were enrolled into the study and prospectively monitored. Complete response (CR) to treatment was defined as platelets >150x109/L for >2 days and LDH normalization, lasting for 30 days; a suboptimal response included exacerbation (EX) = recurrent disease within 30 days after reaching CR; and refractoriness (REF) = no treatment response by day 30. Results: aTTP patient characteristics at diagnosis are shown in the Table. Sixty-three patients were evaluated for treatment response. Two (3%) early deaths were due to myocardial infarction and diffuse rectal ischemia after 7 and 10 days from diagnosis, respectively. Forty patients (64%) obtained a CR after a median time to response (mTTR) of 10 days and a median number of TPE (mTPE) of 7; 21 (33%) obtained a suboptimal response: 13 EX (mTTR 31 days, mTPE 13), and 8 REF (mTTR 42.5, mTPE 19). Thirteen patients with a suboptimal response to TPE were treated with rituximab, all obtaining CR. TTR to 1st line treatment <13 days significantly correlated with a sustained CR (p = 0.004). At remission, 57% of patients showed normal levels (>50%) of ADAMTS13 activity, while 20% a moderate (21–50%), 10% a severe (10–20%), and 11% a complete (<10%) deficiency. A complete or partial recovery of ADAMTS13 activity was associated to negative Ab levels in 90% of cases. Twenty-one patients (34%) relapsed, 14 of them had multiple relapses. Median follow-up was 7 years. Patients were evaluated for predictive parameters of disease recurrence. By multivariate analysis, the association of ADAMTS13 activity ≤20% with a high anti-ADAMTS-13 titer during remission, and a TTR to 1st line treatment ≥13 days, were independent prognostic factors of relapse (p = 0.003 and p = 0.004, respectively). Furthermore, the use of rituximab in patients with a suboptimal TPE response significantly reduced relapse rate (p = 0.002). By Cox regression analysis, patients with ADAMTS13 activity ≤20% plus anti-ADAMTS13 Ab titer >15U/L at remission had an increased risk of relapse (HR 1.98, CI 95% 1.087–3.614; p < 0.02).Summary/Conclusion: In conclusion, our study shows that the association of a low ADAMTS13 activity with high anti-ADAMTS13 antibodies is highly predictive of disease relapse. Moreover, a shorter time to 1st line CR achievement and the salvage use of rituximab in suboptimal responders to TPE significantly reduces relapse. These observations support the use of new therapeutic strategies able to provide faster responses to 1st line TPE treatment in these patients." @default.
• W2949681720 created "2019-06-27" @default.
• W2949681720 creator A5006772521 @default.
• W2949681720 creator A5008630151 @default.
• W2949681720 creator A5020124946 @default.
• W2949681720 creator A5020231170 @default.
• W2949681720 creator A5020467193 @default.
• W2949681720 creator A5031888685 @default.
• W2949681720 creator A5037378269 @default.
• W2949681720 creator A5039927165 @default.
• W2949681720 creator A5042624381 @default.
• W2949681720 creator A5058851458 @default.
• W2949681720 creator A5068459860 @default.
• W2949681720 creator A5068740833 @default.
• W2949681720 creator A5069887195 @default.
• W2949681720 creator A5075340882 @default.
• W2949681720 creator A5085901299 @default.
• W2949681720 creator A5091887568 @default.
• W2949681720 date "2019-06-01" @default.
• W2949681720 modified "2023-09-26" @default.
• W2949681720 title "S1646 THE COMBINATION OF LOW ADAMTS-13 ACTIVITY AND HIGH ANTI-ADAMTS13 ANTIBODIES AT REMISSION HIGHLY PREDICTS DISEASE RELAPSE IN PATIENTS WITH ACQUIRED TTP: A MULTI-INSTITUTIONAL STUDY" @default.
• W2949681720 doi "https://doi.org/10.1097/01.hs9.0000564832.32144.5d" @default.
• W2949681720 hasPublicationYear "2019" @default.
• W2949681720 type Work @default.
• W2949681720 sameAs 2949681720 @default.
• W2949681720 citedByCount "0" @default.
• W2949681720 crossrefType "journal-article" @default.
• W2949681720 hasAuthorship W2949681720A5006772521 @default.
• W2949681720 hasAuthorship W2949681720A5008630151 @default.
• W2949681720 hasAuthorship W2949681720A5020124946 @default.
• W2949681720 hasAuthorship W2949681720A5020231170 @default.
• W2949681720 hasAuthorship W2949681720A5020467193 @default.
• W2949681720 hasAuthorship W2949681720A5031888685 @default.
• W2949681720 hasAuthorship W2949681720A5037378269 @default.
• W2949681720 hasAuthorship W2949681720A5039927165 @default.
• W2949681720 hasAuthorship W2949681720A5042624381 @default.
• W2949681720 hasAuthorship W2949681720A5058851458 @default.
• W2949681720 hasAuthorship W2949681720A5068459860 @default.
• W2949681720 hasAuthorship W2949681720A5068740833 @default.
• W2949681720 hasAuthorship W2949681720A5069887195 @default.
• W2949681720 hasAuthorship W2949681720A5075340882 @default.
• W2949681720 hasAuthorship W2949681720A5085901299 @default.
• W2949681720 hasAuthorship W2949681720A5091887568 @default.
• W2949681720 hasBestOaLocation W29496817201 @default.
• W2949681720 hasConcept C126322002 @default.
• W2949681720 hasConcept C2777014857 @default.
• W2949681720 hasConcept C2777878052 @default.
• W2949681720 hasConcept C2778585876 @default.
• W2949681720 hasConcept C2779134260 @default.
• W2949681720 hasConcept C2779338263 @default.
• W2949681720 hasConcept C2780653079 @default.
• W2949681720 hasConcept C2780921031 @default.
• W2949681720 hasConcept C71924100 @default.
• W2949681720 hasConcept C89560881 @default.
• W2949681720 hasConcept C90924648 @default.
• W2949681720 hasConceptScore W2949681720C126322002 @default.
• W2949681720 hasConceptScore W2949681720C2777014857 @default.
• W2949681720 hasConceptScore W2949681720C2777878052 @default.
• W2949681720 hasConceptScore W2949681720C2778585876 @default.
• W2949681720 hasConceptScore W2949681720C2779134260 @default.
• W2949681720 hasConceptScore W2949681720C2779338263 @default.
• W2949681720 hasConceptScore W2949681720C2780653079 @default.
• W2949681720 hasConceptScore W2949681720C2780921031 @default.
• W2949681720 hasConceptScore W2949681720C71924100 @default.
• W2949681720 hasConceptScore W2949681720C89560881 @default.
• W2949681720 hasConceptScore W2949681720C90924648 @default.
• W2949681720 hasIssue "S1" @default.
• W2949681720 hasLocation W29496817201 @default.
• W2949681720 hasLocation W29496817202 @default.
• W2949681720 hasOpenAccess W2949681720 @default.
• W2949681720 hasPrimaryLocation W29496817201 @default.
• W2949681720 hasRelatedWork W1986381168 @default.
• W2949681720 hasRelatedWork W2124400226 @default.
• W2949681720 hasRelatedWork W2946198964 @default.
• W2949681720 hasRelatedWork W3033753898 @default.
• W2949681720 hasRelatedWork W3037949192 @default.
• W2949681720 hasRelatedWork W3045579636 @default.
• W2949681720 hasRelatedWork W3104949179 @default.
• W2949681720 hasRelatedWork W3159566231 @default.
• W2949681720 hasRelatedWork W4285801222 @default.
• W2949681720 hasRelatedWork W2036500077 @default.
• W2949681720 hasVolume "3" @default.
• W2949681720 isParatext "false" @default.
• W2949681720 isRetracted "false" @default.
• W2949681720 magId "2949681720" @default.
• W2949681720 workType "article" @default.